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ABSTRACT 
Aim 
Our aim was to compare the presence of various common viruses (rhinovirus, enterovirus, 
adenovirus, Epstein-Barr virus, cytomegalovirus, norovirus, parechovirus) in stool and nasal 
swab samples as well as virus-specific antibodies in serum samples between children who 
developed coeliac disease and controls. 
Methods 
A case-control study was established based on the DIABIMMUNE Study cohorts. During the 
study eight Estonian children and 21 Finnish children aged 1.5-5 years developed coeliac 
disease and each was matched with a disease-free control. Nasal swabs and stool samples 
were taken at the age of 3-6 months and the serum samples at the time of diagnosis. 
Results 
Rhinovirus ribonucleic acid was detected in the nasal swabs from five coeliac disease 
children, but none of the control children (p=0.05). There were no statistically significant 
differences in the level of viral antibodies between cases and controls. Enterovirus 
immunoglobulin G class antibodies were found more frequently in the Estonian than in the 
Finnish children (63% versus 23%, p=0.02).  
Conclusion 
This study did not find any marked overall differences in laboratory confirmed common viral 
infections between the children who developed coeliac disease and the controls. However, 
rhinovirus infections were detected slightly more often in those patients who developed 
coeliac disease. 
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KEY NOTES 
• There were no significant differences in laboratory confirmed common viral
infections between the children who developed coeliac disease and the controls
at the age of 1.5-5 years.
• Rhinovirus ribonucleic acid was detected in nasal swab samples of five coeliac
disease children, but in none of the disease-free controls (p=0.05).
• Enterovirus immunoglobulin G class antibodies were found more frequently in the
Estonian than Finnish children (63% versus 23%).
INTRODUCTION 
Coeliac disease is a systemic gluten-driven immune-mediated disorder in genetically 
predisposed subjects carrying the human leukocyte antigen (HLA) DQ2 and, or DQ8 (1). The 
pathogenesis of coeliac disease is complex and not completely understood, but several 
environmental and immunological factors are likely to be involved (2).  
Viral infections are one possible environmental factor. There is growing evidence that 
coxsackieviruses (3) and herpes viruses (4) can be involved in the processes leading to the 
development of different autoimmune diseases, including coeliac disease. Kemppainen et al 
showed a relationship between gastrointestinal infections and increased risk of coeliac 
disease in genetically susceptible children (5). Some data has suggested that herpes viruses 
may have a protective effect on the development of coeliac disease (6). It is also possible 
that the pathogenesis of childhood coeliac disease is influenced by the cumulative effect of 
early-life infections and not just by one specific microbial or viral agent (7,8). Most of these 
studies have been epidemiological (8) and based on parental reports (5,7) and there have 
been very few experimental (9) and laboratory (6) investigations that have shown this 
relationship. However, experimental work by Bouziat et al suggests that the reovirus may be 
related to the development of coeliac disease (9).  
In our previous study, we reported that by the age of 12 months children who later 
developed coeliac disease had more episodes of infections with fever than control children 
(10). The limitation of this study was that the illnesses were reported by the children’s 
parents without laboratory confirmed microbial or viral diagnosis. The aim of our current 
study was to detect viruses in stool and nasal swab samples before the diagnosis and virus-
specific antibodies in serum samples at the diagnosis of coeliac disease. We also wanted to 
compare the frequency of infections in the disease group and disease-free controls with 
similar genetic background and thereby to assess their involvement in the development of 
coeliac disease. 
MATERIALS AND METHODS 
Study subjects 
Our analysis formed part of the international prospective observational DIABIMMUNE Study. 
The study aimed to test the hygiene hypothesis and explore its role in the development of 
type 1 diabetes and other autoimmune diseases. It was originally carried out in Estonia, 
Finland and Russian Karelia from September 2008 to October 2013. As there were no 
biopsy confirmed coeliac disease cases in Russia, that country was not included in this 
study. 
The study included two cohorts: a birth cohort, which observed children from birth up to the 
age of 3 years and a young children cohort who were examined for the first time at the age 
of 3 years and observed to the age of 5 years. The two cohorts comprised different children 
who were observed in parallel during the study period. The exact recruitment criteria have 
previously been described (10). 
As shown in Figure 1, altogether 2,714 infants from maternity hospitals in Estonia and 3,105 
infants in Finland were recruited to the birth cohort. All these children were analysed for type 
1 diabetes and coeliac disease associated HLA DR/DQ alleles (11) from cord blood. If the 
child had eligible HLA genotypes, he or she was invited to follow-up programme. In total, 258 
HLA eligible children in Estonia (61% of all eligible) and 305 in Finland (43% of all eligible) 
completed the 3-year follow-up programme. In the young children cohort, 1,681 children 
from Estonia and 1,575 children from Finland were studied at the age of 3 years and 1,363 
(81%) and 1,384 (88%) children, respectively, attended the follow-up visit at the age of 5 
years. They were all genotyped for type 1 diabetes and coeliac disease associated HLA, but 
recruitment was not based on their genotype. 
During the DIABIMMUNE Study, blood samples were collected by venipuncture at each visit, 
and serum were separated by centrifugation and stored in aliquots at -70ºC for further use. 
Venous blood samples were collected at 3, 6, 12, 18, 24 and 36 months of age in the birth 
cohort and at 3 and 5 years of age in the young children cohort.   
In the birth cohort the parents were asked to collect monthly stool samples at home, starting 
from the age of 1 month. The samples were stored in home freezers at -20ºC immediately 
after the collection until they were transported frozen to the laboratory for long-term storage 
at -80ºC. Also in the birth cohort nasal swabs were collected at study visits by research 
personnel, starting from the age of 3 months, and stored immediately at -20ºC and later at -
80ºC for long-term storage.  
In both cohorts all children were screened for coeliac disease by analysing immunoglobulin 
A (IgA) tissue transglutaminase antibodies (tTG). If there was an equivocal result, for 
example due to low serum volume, haemolytic sample or the IgA-tTG assay could not detect 
any IgA, other tests, including immunoglobulin G (IgG) tTG assays, were applied. The exact 
protocol has previously been described (10). If the result of the antibody test indicated a 
suspicion of coeliac disease, the diagnosis was confirmed in line with the European Society 
for Paediatric Gastroenterology, Hepatology and Nutrition guidelines (1) by abnormal 
morphology of a small intestinal biopsy, in accordance with the Marsh classification modified 
by Oberhuber et al (12).  
During the study period, 29 children developed coeliac disease including two Estonian and 
seven Finnish children in the birth cohort and six Estonian and 14 Finnish children in the 
young children cohort. There were no statistical differences in the mean age at the initial 
seroconversion to IgA-tTG positivity between Estonian and Finnish children in the birth 
cohort (3.0 versus 2.3 years, p=0.12) or in the young children’s cohort (3.6 versus 3.4 years, 
p=0.18) (10). 
For every child with coeliac disease, one disease-free control child from the same 
DIABIMMUNE cohort was selected and matched pair-wise for the coeliac disease specific 
HLA DR/DQ genotype, country of birth, time of birth and sex. The complete characterisation 
of the coeliac disease and control groups has been published previously (10). 
Enterovirus, norovirus, parechovirus and rhinovirus ribonucleic acid (RNA) were analysed in 
the birth cohort from the stool samples collected at the age of 3, 4, 5 and 6 months. In 
addition, enterovirus, parechovirus and rhinovirus RNA were analysed from the nasal swab 
samples collected at the age of 3 and 6 months in the same cohort. IgA and IgG antibodies 
against the norovirus, adenovirus, enterovirus and IgG antibodies against Epstein-Barr virus 
and cytomegalovirus were measured from the serum sample of the children with coeliac 
disease at the time point of seroconversion to positivity for autoantibodies associated with 
coeliac disease in both cohorts. The corresponding serum samples from the control children 
were collected at the same age.  
Laboratory methods 
The HLA DR/DQ genotypes were analysed with a polymerase chain reaction (PCR)-based 
lanthanide labelled oligonucleotide hybridisation method in the Immunogenetics Laboratory, 
University of Turku, Finland, using time-resolved fluorometry for detection as described 
previously (13).  
For screening coeliac disease the autoantibodies associated with coeliac disease were 
analysed. IgA-tTG was measured using ImmunoCAP EliA fully automated solid-phase 
fluoroenzyme immunoassay technology (Phadia AB, Uppsala, Sweden) in accordance 
with a specific and previously described protocol (10). We considered samples with 
values higher than 10 EliA U/ml positive. The analyses were performed in the 
Department of Immunology, University of Tartu, Estonia. 
We screened for enterovirus and rhinovirus RNA from stool and nasal swab samples using 
real time reverse transcription PCR (RT-PCR). In addition, we tested for parechovirus and 
norovirus RNA in the stool samples using specific RT-PCR methods (parechovirus also from 
nasal swab). Stool samples were suspended in a concentration of 10% in HANKS solution 
(Sigma-Aldrich, Missouri, USA) and RNA was extracted using the viral RNA kit (Qiagen, 
Hilden, Germany). QuantiTect Probe reagents (Qiagen, Hilden, Germany) were used 
according to the manufacturer’s instructions for amplification of virus RNA. All the samples 
were run in triplicate and, if any of the reaction was positive, that sample was regarded as 
positive for the tested virus. Primer and probe sequences, as well as the concentrations in 
the reactions, were reported by Krogvold et al (14). That study recorded two primer pairs for 
enterovirus detection, but in our study the primer pair of fwd 636 and rev 4- was used. The 
analysis was carried out in the Virus Laboratory, University of Tampere, Finland. 
The analysis of norovirus, adenovirus and enterovirus IgA and IgG antibodies in serum was 
carried out in the Virus Laboratory, University of Tampere, Finland, by indirect enzyme-
linked immunosorbent assay (ELISA). All samples were tested in pairs. Samples from the 
case and control child were included in the same test run, without knowing the case-control 
status of the child. The level of anti-viral IgA and IgG is expressed as enzyme immunoassay 
units (EIU). 
Briefly, 96-well half-area polystyrene plates (Corning Incorporated, New York, USA) were 
used for norovirus antibody analyses and Nunc-Immuno MaxiSorp plates (Thermo Fisher 
Scientific, Massachusetts, USA) for adenovirus and enterovirus antibody analyses. For 
norovirus antibody analyses, the plates were coated with norovirus virus-like particle 
antigens at a concentration of 1 μg/ml in phosphate-buffered saline (pH 7.2) as previously 
described (15). For adenovirus antibody analyses an adenovirus hexon antigen was used at 
a concentration of 0.32 μg/ml in phosphate-buffered saline (pH 7.2) (16) and for enterovirus 
a sucrose gradient purified coxsackievirus B4 was used at a concentration of 0.76 μg/ml in 
carbonate buffer (17). Norovirus antibodies were analysed using 1/200 (IgA) and 1/4000 
(IgG) serum dilutions in 1% milk + 0.05% Tween 20 (MP Biomedicals, Illkirch, France) in 
phosphate-buffered saline and adenovirus and enterovirus antibodies using 1/100 (IgA) and 
1/2000 (IgG) dilutions in phosphate-buffered saline supplemented with 1% bovine serum 
albumin (Sigma-Aldrich, Missouri, USA), 2% sodium chloride and 0.05% Tween 20. For 
norovirus IgA, the detection antibodies were goat anti-human IgA-horseradish peroxidase 
(Pierce cat PA1-74395, Thermo Fisher Scientific, Massachusetts, USA) and for IgG goat 
anti-human IgG-HRP (Invitrogen cat 627120, Invitrogen, California, USA). For adenovirus 
and enterovirus IgA, Dako P0216 rabbit anti-human IgA-HRP (Dako, Glostrup, Denmark) 
and for IgG Dako P0214 rabbit anti-human IgG-HRP (Dako, Glostrup, Denmark) were used. 
Absorbance at 490 nm (norovirus, adenovirus) or 492 nm (enterovirus) was measured on a 
Victor2 microplate reader (PerkinElmer, Massachusetts, USA). 
Cut-off limits for the virus antibody analyses were determined by arrangement of the optical 
density results in ascending order to generate a histogram (Figure S1). The abrupt increase 
of the optical density values was used to separate positive and negative values. The 
arbitrary negative values were used to calculate the final cut-off using the formula: the mean 
of the arbitrary optical density negative value + three standard deviations (SD). The cut-off is 
shown with an arrow on the histograms. All the values above the set cut-off value were 
considered as positive. 
For cytomegalovirus IgG and Epstein-Barr virus viral capside antigen IgG detection we used 
ELISA in accordance with the manufacturer’s protocol, by employing the LUCIO-Sero ELISA 
Cytomegalovirus IgG and the LUCIO-Sero ELISA Epstein-Barr VCA IgG (nal von minden 
GmbH, Moers, Germany). The results were calculated according to the manufacturer’s 
instructions. Equivocal cytomegalovirus IgG results were demonstrated in a child with 
coeliac disease in the birth cohort from Estonia and this child was excluded from the final 
analysis.  
Statistical analysis 
The statistical analysis was performed with R software for Windows 2016 (R Foundation for 
Statistical Computing, Vienna, Austria). To analyse differences in antibody levels between 
the coeliac disease and control groups we used the paired t-test or the Wilcoxon signed-rank 
test. The paired t-test was used for norovirus and enterovirus IgA antibodies comparisons in 
the birth cohort and enterovirus IgG antibodies comparisons in both cohorts in cases where 
IgA-tTG was higher than 100 U/ml. The Wilcoxon signed-rank test was used for all other 
comparisons between the coeliac disease and control groups. Odds ratios (OR) were used 
to assess the risk of coeliac disease. Conditional logistic regression was applied to calculate 
adjusted ORs (aOR). 95% confidence intervals (CI) were used to estimate the precision of 
the aORs. Correlations between the level of virus IgA or IgG antibodies and the level of IgA-
tTG were analysed with the non-parametric Spearman test. We compared the antibody 
levels between the Estonian and Finnish children with the Mann-Whitney-Wilcoxon test. To 
compare the number of cases with antibodies or viruses in the different study groups, the 
Fisher’s exact test or the chi-square test was applied. The Shapiro-Wilk normality test was 
used to determine if the data had a normal distribution. A p value of less than 0.05 was 
considered significant. 
Ethical considerations 
The study was conducted in accordance with the ethical guidelines of the Declaration of 
Helsinki. The local ethical committees in Estonia and Finland approved the study. All the 
parents gave written, informed consent for their child to participate in the study.  
RESULTS 
Viruses in stool and nasal swab samples 
In the birth cohort, 13/120 (11%) of the serial stool samples from children who developed 
coeliac disease were virus positive, compared to 14/120 (12%) of the stool samples from the 
controls (p=1.0). From the cases 5/43 (12%) nasal swabs were virus positive, compared to 
none of the 36 nasal swab samples from the controls (p=0.06). At least one viral agent was 
detected in either the stool or nasal swab samples of 7/9 (78%) children in the coeliac 
disease group and in 6/9 (67%) children in the control group (p=1.0). The rhinovirus was the 
virus that was detected most frequently in both the stool and nasal swab samples. At the age 
of 3 and 6 months, 8/33 (24%) samples from the children with coeliac disease and 7/32 
(22%) samples from the control children contained some rhinovirus when the stool and nasal 
swab samples were combined. There were 5/18 (28%) rhinovirus positive nasal swabs in the 
cases and none in the 16 controls (p=0.05). In the stool samples, the corresponding figures 
were 3/15 (20%) and 7/16 (44%) (p=0.25). Enterovirus and parechovirus were not detected 
in any sample (Figure 2). 
Viral antibody differences between the coeliac disease and control group 
There were no statistically significant differences in the level of viral antibodies, or the 
number of positive cases, between the case and control children in the birth cohort or the 
cohort of young children or when the two cohorts were combined (Figure 3). When the 
norovirus, adenovirus and enterovirus IgA positive cases were combined in the birth cohort, 
the case children had a mean of 1.6 infections and the controls had a mean of 1.2 infections 
(p=0.55). The mean number of positive tests for IgG antibodies to these viruses was 1.4 and 
1.0 (p=0.33), respectively. In the cohort of young children the mean number of positive tests 
did not differ between the coeliac disease and control groups (1.7 versus 1.8 for IgA, p=0.67, 
and 1.5 versus 1.7 for IgG, p=0.38). There was no difference in the cytomegalovirus and 
Epstein-Barr virus IgG antibodies between the groups. When using the aOR and 95% CI 
none of the measured virus antibodies affected the risk of coeliac disease in the birth cohort, 
in the young children cohort or in the combined cohort (data not shown). There was no 
association between the level of virus IgA or IgG antibodies and the level of IgA-tTG (data 
not shown).  
When we only took coeliac disease cases into account, where IgA-tTG was higher than 100 
U/ml, there were no differences in viral antibodies between the coeliac disease and control 
group. 
Viral antibody differences between Estonia and Finland 
The study included 42 children from Finland and 16 children from Estonia. When the 
different virus antibodies were compared between the two countries, enterovirus IgG class 
antibodies were found to be much more frequent in Estonian children (63% versus 23%, 
p=0.02).  The same difference was seen in average enterovirus IgG antibody levels (34.5 
EIU versus 19.0 EIU, p=0.01) (Figure 4). A similar, but non-significant, trend was also seen 
in enterovirus IgA antibodies (56% versus 38%, p=0.54 and 61.2 EIU versus 35.3 EIU, 
p=0.31). Other virus antibodies did not differ between the countries. 
DISCUSSION 
This study was an extension of our earlier study where we compared the occurrence of 
prospectively reported infections between children who developed coeliac disease and 
matched control children with no disease. In that study the children who developed coeliac 
disease during the first 3 years of life had more infections with fever during their first 12 
months (10). In our current study we set out to analyse which of the most common infections 
might be involved, by detecting enterovirus, parechovirus, norovirus and rhinovirus in stool 
 
and nasal swab samples collected from case and control children before the diagnosis of 
coeliac disease. We also measured IgA and IgG antibodies in the serum to norovirus, 
adenovirus, enterovirus and IgG antibodies to cytomegalovirus and Epstein-Barr virus in the 
same groups at the time of the diagnosis of coeliac disease in the cases.  
The main finding was that the overall level and frequency of the gastrointestinal virus 
antibodies did not differ between the patients and controls. Some previous studies have 
been published that have reported possible relationships between different gastrointestinal 
infections and coeliac disease. Kemppainen et al found that gastrointestinal infections might 
increase the risk of coeliac disease in genetically susceptible children (5). Stene et al (18) 
reported in their prospective study that rotavirus infections might be involved. We did not add 
the rotavirus to the analyses in this study since the rotavirus vaccination coverage was very 
different between the cases and controls and there were very few pairs that had the same 
vaccination status. There have been no studies about a potential association between the 
norovirus and coeliac disease. Some studies have shown an association between 
adenovirus type 12 (Ad 12) and coeliac disease (19), but this was not confirmed in other 
studies (20). However, all these studies are quite old. Carlsson et al studied the cord blood 
of the mothers whose offspring later developed coeliac disease and did not find any 
association between enterovirus infection during pregnancy and the development of coeliac 
disease during childhood (21). On the other hand, one study reported enterovirus genomes 
in intestinal biopsies collected from coeliac disease patients (22). The Generation R Study 
found that herpesviruses may have a protective effect in the development of coeliac disease 
(6). We could not find such an association in our study by measuring IgG antibodies against 
cytomegalovirus and Epstein-Barr virus.  
However, when we combined seropositivity for at least one of the tested viruses in serum, 
these tended to be more common in coeliac disease patients than in controls, with a mean of 
1.6 versus 1.2 infections per child, in the birth cohort. This may indicate that there was some 
cumulative effect of early infections, as indicated in previous epidemiological studies 
(7,8,10). 
In nasal swab samples, rhinoviruses were detected slightly more frequently in coeliac 
disease patients than in controls, but this was not the case for stool samples. Rhinoviruses 
replicate in the respiratory tract at relatively low temperatures, but they are not known to be 
able to replicate in the intestinal mucosa where the temperature is substantially higher. 
Therefore, respiratory samples are considered to be the most reliable sample type for 
rhinovirus detection. We cannot exclude the possibility that certain rhinovirus species, such 
as species C, could also replicate at higher temperatures, such as those present in the 
intestinal mucosa (23). Notably, the main rhinovirus receptor intercellular adhesion 
molecules-1 (24) is also expressed in intestinal mucosa in coeliac disease (25). One could 
hypothesise that rhinovirus infection may increase the expression of intercellular adhesion 
molecules-1 in the intestinal mucosa and thereby facilitate leukocyte migration towards 
infection sites, including gliadin sensitised T cells.  
When we compared the Finnish and Estonian children, this revealed that the Estonian were 
more likely to test positive for enterovirus IgG. Importantly, the mean levels of the antibodies 
were significantly higher in the Estonia cohort than in Finland. This finding was in line with 
our previous studies (26). It has been reported that type 1 diabetes is more frequent in 
Finland (27) than in Estonia (28). Enteroviruses may play a role in the pathogenesis of 
autoimmune beta-cell destruction in type1 diabetes (29). We have previously shown that the 
5-year cumulative incidence of childhood coeliac disease was significantly higher in Finland 
than in Estonia (0.77% versus 0.27%, p=0.01) (10). Accordingly, both coeliac disease and 
type 1 diabetes are more frequent in Finland than Estonia, but enterovirus antibodies are 
less frequent. The low prevalence of enterovirus infections in Finland may cause deficient 
immune protection by transferred maternal antibodies in early childhood, which might make 
Finnish children more susceptible to early enterovirus-induced diseases, as proposed in 
earlier studies (26).  
 
When we considered the relationship between the low prevalence of enterovirus infection 
and the high prevalence of type 1 diabetes and coeliac disease, we felt that this may reflect 
the hygiene hypothesis. This was because in countries where enterovirus infections are 
frequent, children had strong immune responses to these viruses, and the incidence of type 
1 diabetes and coeliac disease was lower (30). This fits with the so-called polio hypothesis 
reported in a previous study (31). That study reported that in cases of poliomyelitis, a well-
known disease caused by an enterovirus, severe paralytic complications were more 
common in countries where the circulation of the virus in the background population was 
less frequent.  
Our study had some limitations, which need to be considered when interpreting the results. 
First, the number of coeliac disease cases was relatively low and this limited the statistical 
power. Although the original DIABIMMUNE Study was prospective, the current survey is a 
retrospectively matched case-control study that has some disadvantages related to that type 
of studies. In addition, we did not have the chance to collect serial stool and nasal swab 
samples from every child we studied at all time points. The limited number of study samples 
reflects the problems related to collecting samples from young children. In addition, the 
present study did not cover all the possible viruses that could be linked to coeliac disease.  
The main strength of our study was the prospective design in the DIABIMMUNE Study and 
the well-synchronised and carefully followed study protocols in both countries. Another 
strength was the careful matching of the children with coeliac disease and the control 
subject. Importantly all the coeliac disease cases were confirmed by small intestinal biopsy 
and specific laboratory analyses were carried out in one laboratory.  
CONCLUSION 
This study did not find any marked difference in laboratory confirmed common viral 
infections, namely enterovirus, adenovirus, Epstein-Barr virus, cytomegalovirus, norovirus 
and parechovirus infections, between the children who developed coeliac disease and their 
matched controls. However, rhinovirus infections were observed to be slightly more frequent 
in the coeliac disease patients than in the controls. As our study population was small, larger 
studies are needed to confirm this particular finding. In addition, our study confirms earlier 
findings of a significantly higher prevalence of enterovirus infections in Estonian children 
than in their Finnish peers. 
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Figure 1. Study outline with relevant data about subjects and methods 
Figure 2. Virus test results in stool and nasal swab samples in the birth cohort at the 
age of 3 and 6 months  
(• - coeliac disease child, ◊ - control child, En – enterovirus, Pa – parechovirus, Rh – 
rhinovirus, NoV – norovirus, CD – coeliac disease) 
Figure 3. Number of positive cases and the median (shown as a dot), minimum 
(minimum point of the line) and maximum (maximum point of the line) level of IgA and 
IgG antibodies in the coeliac disease and control groups 
(CD – coeliac disease child) 
Figure 4. Number of positive cases and the median (shown as a dot), minimum 
(minimum point of the line) and maximum (maximum point of the line) level of IgA and 
IgG antibodies between Estonian and Finnish children 
(* - statistically significant difference) 
Figure S1 (a-f). Histograms showing optical density results in ascending order and an 
arrow showing the cut-off of positive and negative values - a) norovirus IgA, b) 
norovirus IgG, c) adenovirus IgA, d) adenovirus IgG, e) enterovirus IgA, f) enterovirus 
IgG 
(OD – optical density) 




